|
Re: Lu stepping down
|
6
|
Resverlogix Corp.
|
Feb 22, 2024 07:11PM
|
|
Re: RVX Announces Update Webcast and Conference Call
|
6
|
Resverlogix Corp.
|
Jan 18, 2021 04:05PM
|
|
Re: BTD
|
6
|
Resverlogix Corp.
|
Apr 23, 2022 03:10PM
|
|
Re: IR - "but all I can tell you at the moment is that we believe we are making real progress towards achieving our goals."
|
6
|
Resverlogix Corp.
|
May 11, 2023 02:18PM
|
|
Re: Resverlogix Announces US$30 Million Loan Commitment Letter .
|
6
|
Resverlogix Corp.
|
Apr 11, 2018 08:34AM
|
|
Re: New Phase 1 NCI trial
|
6
|
Zenith Epigenetics
|
May 24, 2023 07:09PM
|
|
Re: AAIC and MD&A
|
6
|
Resverlogix Corp.
|
Jul 24, 2018 08:34AM
|
|
Re: There's a proposal waiting for Don when he gets back....
|
6
|
Resverlogix Corp.
|
Jun 07, 2018 06:55PM
|
|
Zenith AGM
|
6
|
Zenith Epigenetics
|
Dec 20, 2016 09:32AM
|
|
Re: Zenith share issue
|
6
|
Zenith Epigenetics
|
Nov 14, 2017 01:11PM
|
|
Re: Futility Analysis Q&A With Company Source
|
6
|
Resverlogix Corp.
|
Feb 18, 2016 07:37PM
|
|
major disconnect in Share price/value to other biotech is same space
|
6
|
Resverlogix Corp.
|
Aug 20, 2015 11:11AM
|
|
Re: New paper
|
6
|
Resverlogix Corp.
|
Mar 19, 2023 11:52AM
|
|
Re: Priceless on I.V. Regarding Zenith
|
6
|
Zenith Epigenetics
|
Apr 09, 2017 12:03PM
|
|
Re: No trading yet on the TSX
|
6
|
Resverlogix Corp.
|
Oct 27, 2017 11:35AM
|
|
Royalty deals with Pharma
|
6
|
Resverlogix Corp.
|
Feb 08, 2024 09:22AM
|
|
Re: Trial
|
6
|
Zenith Epigenetics
|
Nov 21, 2019 01:49PM
|
|
FA and loan extention
|
6
|
Resverlogix Corp.
|
Jun 26, 2017 12:38PM
|
|
Re: 2 year extension
|
6
|
Resverlogix Corp.
|
May 14, 2024 12:43PM
|
|
Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV
|
6
|
Zenith Epigenetics
|
Feb 22, 2022 10:24AM
|
